is tirzepatide a glp-1 drug Use of the dual GIP/GLP-1 (Mounjaro, Zepbound) was associated with significantly reduced risk of glaucoma compared with drugs among patients with type 2 diabetes, a large retrospective cohort A Major GLP-1 Drug Shortage

Primary outcomes included serious adverse events and retained gastric products based on patient records, procedure reports, and procedural videos

Currently, the Food and Drug Administration (FDA) has approved seven GLP-1 prescription medications:GENERIC NAMEBRAND NAMEFORMSSemaglutideOzempicRybelsusWegovyInjectionOral PillTirzepatideMounjaroZepboundInjectionLiraglutideVictozaSaxendaInjectionDulaglutideTrulicityInjectionExenatideByettaInjectionLixisenatideAdlyxinInjectionOrforglipron*Foundayo*Oral Pill*Non-peptide, small molecule When used in addition to a reduced calorie diet and increased physical activity, these medications are FDA approved for one or more of the following:Improving blood sugar levels in adults with T2D.Reducing excess body weight and keep it off long term in:Adults and children aged 12 years and older with obesity.Adults who are overweight who also have at least one weight-related medical problem (such as high blood pressure, diabetes, or high cholesterol)Reducing the risk of major adverse cardiovascular events in adults with T2D who have heart disease or are at high risk for these events.Can Service Members use GLP-1 prescription medications?GLP-1 medications are only available with a prescription from a qualified healthcare provider

Compare total program costs, pharmacy credentials, and clinical oversight before enrolling.

Weight loss was consistent across all demographics

The aim of this literature review is to discuss evidence from basic science, human studies, and clinical trials to support the preferential use of GLP-1 RAs in asthma patients with co-occurring diabetes and obesity